Health System

In the previous installment about the molecular medicine conference, I emphasized that the science of so-called complex, polygenic diseases like cancer is, well, complex. But there are other complications as well in the life science business. Biotechnology and pharmaceuticals are also risky, complicated enterprises from a financial standpoint. In a way it’s kind of a layering of complexities, one atop ...

I had the good fortune to attend (thanks to FI Center) the “Molecular Medicine Tri-Conference” in San Francisco last week. The attendees were researchers, executives of biotech and pharmaceutical companies, a few scientists from NCI or NIH, and me—as far as I can tell, the single NGO nonprofit person. (That’s not to say all the companies present are turning a ...

Colonoscopy Parties Remove Fear Factor The title tells the story. A potential volunteer program?

You need a subscription to access this Wall Street Journal article, but I’ll quote liberally. Support for a change in how health-care coverage is presently provided appears to be growing among many diverse constituencies, including both Republicans and Democrats. The reasons are easy enough to understand. With average health-insurance premiums for families potentially accounting for 21% of median household income, ...